Publications by authors named "Andra Cirule"

Claim this Profile
F
Fluctuations in circulating cell-free mitochondrial and nuclear DNA copy numbers in blood plasma after anti-tuberculosis drug intake in patients with drug-susceptible tuberculosis.
Lauma Freimane, Agnija Kivrāne, Viktorija Ulanova, Anda Vīksna, Eduards Sevostjanovs

Tuberculosis (Edinb)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Viktorija Ulanova, Agnija Kivrane, Anda Viksna, Leonora Pahirko, Lauma Freimane, Andra Cirule

Front Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
Agnija Kivrane, Solveiga Grinberga, Eduards Sevostjanovs, Viktorija Igumnova, Ilva Pole, Andra Cirule

J Chromatogr B Analyt Technol Biomed Life Sci· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Florian von Groote-Bidlingmaier, Ramonde Patientia, Epifanio Sanchez, Vincent Balanag, Eduardo Ticona, Andra Cirule

Lancet Respir Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Lancet· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.
Giovanni Battista Migliori, Giovanni Sotgiu, Senia Rosales-Klintz, Rosella Centis, Lia D'Ambrosio, Andra Cirule

Eur Respir J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
Viktorija Igumnova, Valentina Capligina, Alvils Krams, Andra Cirule, Didzis Elferts

J Infect Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study.
Helen R Stagg, James Brown, Elmira Ibraim, Vija Riekstiņa, Piret Viiklepp

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.
Helen R Stagg, Peter J White, Vija Riekstiņa, Andra Cīrule, Ģirts Šķenders

Emerg Infect Dis· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.
J Peter Cegielski, Ekaterina Kurbatova, Martie van der Walt, Jeannette Brand, Julia Ershova, Andra Cirule

Clin Infect Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Thelma Tupasi, Rajesh Gupta, Manfred Danilovits, Andra Cirule, Epifanio Sanchez-Garavito

Bull World Health Organ· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delamanid for Extensively Drug-Resistant Tuberculosis.
Rajesh Gupta, Lawrence J Geiter, Charles D Wells, Mengqui Gao, Andra Cirule

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Andra Cirule

Eur Respir J· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia.
Thaddeus L Miller, Andra Cirule, Fernando A Wilson, Timothy H Holtz, Vija Riekstina

Cost Eff Resour Alloc· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis